ALK and lung cancer: As targeted agents continue to be developed, there is evidence that inhibitors of ALK, such as crizotinib and alectinib, can demonstrate efficacy in the treatment of nonsmall cell lung cancer and myofibroblastic tumors due to ALK rearrangements [74,75,76].